Opioid Settlement Payouts: Why Thousands of Victims Are Still Waiting for Compensation
Mary Jannotta spent decades slicing meat and cheese behind supermarket deli counters in the Philadelphia suburbs, her back aching from years of standing. A botched surgery in 2008 left her in chronic pain, and her doctor prescribed OxyContin—the high-dose opioid later at the center of Purdue Pharma’s criminal guilty plea for deceptive marketing. What began as a medical necessity spiraled into addiction. Cut off by her doctors, Jannotta turned to Philadelphia’s open-air drug markets to feed her dependence. She lost her car, her home, and—most devastatingly—her grandson, Tyler Cordeiro, who died of an overdose at 24 after stealing her prescription pills as a teenager.
When Purdue Pharma filed for bankruptcy in 2019, Jannotta joined nearly 140,000 others in filing claims against the company, seeking financial redress for the harm its drugs had caused. For victims like her, the settlements represented more than money—they were a rare chance for accountability from Purdue and its billionaire owners, the Sackler family. But after years of legal limbo, many are discovering that justice remains elusive. A 2024 U.S. Supreme Court ruling blocked the initial settlement, which would have shielded the Sacklers from future lawsuits. While a revised plan was approved in November 2025, payouts have only just begun—and for thousands, the wait continues.
This is not just Purdue’s story. Two other major opioid manufacturers, Mallinckrodt and Endo, have also sought bankruptcy protection to resolve their own legal liabilities. Their settlements, though smaller, have left victims navigating a labyrinth of court-appointed trusts, eligibility criteria, and delayed disbursements. If you or someone you grasp has filed a claim with Purdue, Mallinckrodt, or Endo and is still waiting for compensation, your experience matters. Investigative journalists are gathering firsthand accounts to uncover how these settlements are—or aren’t—delivering on their promises.
The Purdue Pharma Settlement: A Fund Eight Times Larger—But Still Insufficient
The Purdue Pharma bankruptcy estate is the largest of the three major opioid settlements, with a $6 billion fund earmarked for victims, states, and local governments. To put that in perspective, it is more than eight times the combined payouts from Mallinckrodt and Endo. Yet despite its size, the fund is already straining under the weight of demand. Nearly 140,000 personal injury claims were filed, but the trust’s administrators have warned that payments may be capped at as little as $3,500 per claimant—a fraction of what many had hoped for.
The delays are not just bureaucratic. The Sackler family, which withdrew billions from Purdue before the bankruptcy, initially sought immunity from future lawsuits—a provision the Supreme Court struck down in 2024. The revised settlement, approved in late 2025, removed that shield but left the family’s contributions largely intact. Critics argue that the Sacklers, who have never faced criminal charges, are still escaping full accountability. As one victim advocate told the Philadelphia Inquirer, “The money is a Band-Aid. The real wound is that the people who profited from this crisis are walking away.”
For Jannotta and others, the settlement’s limitations are personal. “I don’t know what $3,500 is supposed to fix,” she said in a recent interview. “It won’t bring Tyler back. It won’t cover the years of therapy I needed. But it’s something—and right now, it’s all we’ve got.”
Mallinckrodt and Endo: Smaller Settlements, Similar Struggles
While Purdue’s bankruptcy has dominated headlines, Mallinckrodt and Endo have also faced waves of litigation over their roles in the opioid epidemic. Both companies filed for bankruptcy in 2020, seeking to resolve thousands of lawsuits through court-approved trusts. Yet their payouts have been slower to materialize—and far smaller in scale.
Mallinckrodt: A $1.7 Billion Fund, But Delays Persist
Mallinckrodt, an Ireland-based pharmaceutical company, reached a $1.7 billion settlement agreement in 2022, with funds designated for states, local governments, and individual victims. However, the trust responsible for distributing payments has faced repeated delays. As of April 2026, only a fraction of claimants have received compensation, with many still awaiting updates on their cases. The company’s bankruptcy plan, approved in 2023, included provisions for a victim compensation fund, but administrative hurdles have slowed disbursements.
Endo: A $450 Million Fund—And a Warning of Insufficient Funds
Endo International, another major opioid manufacturer, filed for bankruptcy in 2022 and reached a $450 million settlement in 2023. Like Mallinckrodt, its trust has struggled to process claims efficiently. In a February 2026 filing, the trust’s administrators warned that funds may be insufficient to cover all approved claims, raising the possibility of further reductions in payouts. For victims who have already waited years, the news was another blow.
“It’s like being told you’re in line for a lifeboat, only to find out the boat is sinking,” said one claimant, who asked to remain anonymous. “We were promised this money would help us rebuild. Now we’re being told there might not be enough to go around.”
Who Qualifies for Compensation—and Who Gets Left Out?
The opioid settlements were designed to compensate a broad range of victims, including:
- Individuals who became addicted to prescription opioids
- Families of those who died from opioid-related overdoses
- Healthcare providers and first responders affected by the crisis
- Communities that bore the social and economic costs of addiction
However, eligibility criteria vary by trust, and not all claimants will receive the same amount—or any payment at all. For example:
- Purdue’s trust prioritizes claims based on the severity of harm, with higher payouts for those who can document long-term addiction or overdose deaths in their families. However, the sheer volume of claims means many will receive only a fraction of what they sought.
- Mallinckrodt’s trust has faced criticism for its opaque review process, with some claimants reporting that their applications were denied without clear explanation.
- Endo’s trust has warned that payouts may be reduced if the fund is oversubscribed, leaving some victims with little recourse.
For those who have already filed claims, the waiting game is far from over. Many have reported difficulty tracking the status of their applications, with some trusts providing little to no transparency. “I’ve called the trust’s hotline a dozen times,” said one claimant. “Every time, I’m told my case is ‘under review.’ But no one can tell me what that means or when I might hear something.”
How the Opioid Crisis Was Fueled—And Why These Settlements Matter
The opioid epidemic did not happen by accident. Investigations by the U.S. Department of Justice, state attorneys general, and journalists have revealed how pharmaceutical companies aggressively marketed opioids while downplaying their risks. Purdue Pharma, in particular, has admitted to misleading doctors and regulators about OxyContin’s addictive potential, including falsely claiming that the drug’s 12-hour pain relief reduced the risk of addiction.
In reality, as a 2016 investigation by the Los Angeles Times revealed, OxyContin’s effects often wore off after just 4–6 hours, leading patients to take higher doses—and increasing the risk of overdose. The company’s own internal documents showed that Purdue was aware of this issue but continued to promote the 12-hour dosing schedule as a selling point.
The consequences have been devastating. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 645,000 people died from opioid overdoses in the U.S. Between 1999 and 2022. The crisis has also strained healthcare systems, devastated families, and left communities grappling with the social and economic fallout of addiction.
For victims and their families, the settlements represent a rare opportunity for financial relief—and a measure of justice. But as the delays and limitations of the payouts become clear, many are questioning whether the system is truly designed to help those who need it most.
What Happens Next? Key Dates and Deadlines
If you’ve filed a claim with Purdue, Mallinckrodt, or Endo, here’s what you need to know about the road ahead:
- Purdue Pharma Trust: Initial payouts began in early 2026, but the trust has warned that funds may be exhausted by mid-2027. Claimants are encouraged to check the official trust website for updates.
- Mallinckrodt Trust: The trust is still processing claims, with no firm timeline for disbursements. Some claimants have reported receiving partial payments, but many are still waiting for resolution.
- Endo Trust: The trust has begun distributing funds, but administrators have warned that payouts may be reduced if the fund is oversubscribed. Claimants should monitor the trust’s website for updates.
For those who have not yet filed a claim, deadlines vary by trust. The Purdue trust, for example, has closed its initial claim period, but late claims may still be considered in some cases. The Mallinckrodt and Endo trusts are still accepting applications, but claimants are urged to act quickly, as deadlines may be approaching.
Share Your Story: How Has the Settlement Process Affected You?
If you or someone you know has filed a claim with Purdue, Mallinckrodt, or Endo—and is still waiting for compensation—your experience could help shape the public understanding of these settlements. Investigative journalists at the Philadelphia Inquirer and ProPublica are gathering firsthand accounts to uncover how these trusts are functioning, who is being left behind, and what can be done to improve the process.
Have you faced delays, denials, or unexpected reductions in your payout? Have you struggled to navigate the claims process? Your story could help others in similar situations—and hold the system accountable.
To share your experience, visit ProPublica’s callout page. Your identity will be kept confidential if requested.
Key Takeaways: What You Need to Know
- The Purdue Pharma settlement is the largest of the three major opioid payouts, with a $6 billion fund, but nearly 140,000 claimants mean individual payouts may be as low as $3,500.
- Mallinckrodt and Endo have smaller funds ($1.7 billion and $450 million, respectively), but both trusts have faced delays and warnings of insufficient funds.
- Eligibility varies by trust, with some claimants receiving full payouts while others are denied or offered reduced amounts.
- Transparency remains a major issue, with many claimants reporting difficulty tracking the status of their applications.
- Deadlines are approaching for some trusts, so claimants are urged to check official websites for updates.
What’s Next?
The next major checkpoint for the opioid settlements will be the mid-2026 progress reports from the Purdue, Mallinckrodt, and Endo trusts. These reports are expected to provide updated figures on payouts, claim denials, and fund balances. For claimants still awaiting resolution, these reports could offer critical insights into whether the trusts will have enough money to cover all approved claims.
In the meantime, if you’ve been affected by the opioid crisis and are navigating the settlement process, your voice matters. Share your story, stay informed, and demand accountability from the trusts responsible for distributing these funds. The fight for justice is far from over—but together, One can ensure that the stories of those who have suffered are not forgotten.
Have you been affected by the opioid settlements? Share your thoughts in the comments below, and help us spread the word by sharing this article with others who may be waiting for answers.